| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778440 | European Urology | 2018 | 9 Pages |
Abstract
Combining chemotherapy and immune checkpoint blockade in patients with metastatic urothelial cancer is feasible. Further studies are needed to refine optimal combinations and evaluate tests that might identify patients most likely to benefit.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Matthew D. Galsky, Huan Wang, Noah M. Hahn, Przemyslaw Twardowski, Sumanta K. Pal, Costantine Albany, Mark T. Fleming, Alexander Starodub, Ralph J. Hauke, Menggang Yu, Qianqian Zhao, Guru Sonpavde, Michael J. Donovan, Vaibhav G. Patel, John P. Sfakianos,